Company & Sponsor Intelligence
Queen Mary University of London
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting1
Completed3
Countries2
Therapeutic footprint
multiple_sclerosisout_of_scopeparkinsons
Indexed studies
NCT02880982Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
out_of_scope · South AfricaPHASE3
out_of_scope · South AfricaPHASE3
NCT06174948The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders
parkinsons · United KingdomNA
parkinsons · United KingdomNA
NCT01991314Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
out_of_scope · United KingdomPHASE4
out_of_scope · United KingdomPHASE4
NCT01767701Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
multiple_sclerosis · United KingdomPHASE2
multiple_sclerosis · United KingdomPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →